

International Journal of Multidisciplinary Research in Biotechnology,
Pharmacy, Dental and Medical Sciences (IJMRBPDMS)

**CRISPR-Cas9 as a Potential Tool for Precision Medicine:
Challenges and Future Directions**

Dasari Karthik Kumar

Sree Dattha Institute of Pharmacy
Ibrahimpattanam, Ranga Reddy District
Telangana, India – 501510
Email: dasarikarthik3@gmail.com

ABSTRACT

The recent discovery of CRISPR-Cas9, a revolutionary gene-editing technology has served as a game-changer in biomedical research since it provides a certain level of precision never before possible in genome editing. In an effort to almost perfectly target specific genetic conditions, CRISPR, as an enabling technology, has a lot of promise in rectifying genetic conditions, refining treatment delivery, and personalizing treatment decisions based on an individual's genetic signature. The present paper examines how CRISPR-Cas9 can be used in precision medicine, outlining its transformative power, limitations and the issues that characterize the use of such a technology in clinical practice. In spite of its effectiveness in preclinical models, safety concerns of off-target effects, ethical issues, and delivery problems continue to present obstacles to the widespread application of its use in clinical settings. The paper contains further detail of progress towards greater specificity and efficacy of CRISPR, along with a detailed overview of where the technique is already used or is anticipated to be used in terms of personalized medicine in the future. The other important considerations including safety, regulatory frameworks, and acceptance that have been raised in the context of clinical translation of CRISPR are also discussed. The proposed research area seeks to illuminate on the ways in which CRISPR-Cas9 may be idealized to be used in a clinic setting as it walks through the intricacies of applying the same to genetic illnesses. The discussion is ended with a glance of future outlook of CRISPR in precision medicine, in regard of whether it could help in treating complex diseases such as cancer, genetic and multifactorial conditions.

Keywords: *CRISPR-Cas9, precision medicine, gene editing, therapeutic applications, genetic disorders.*

1. Introduction

The recent surge in the development of CRISPR-Cas9 as a genome editing technology and bacterial immune system have created limitless opportunities of exact genetic modification, thus speeding up research in a wide range of scientific fields, such as biomedical research and agriculture (Wang & Doudna, 2023) (Chen et al., 2019). The technology enables specific changes to be made to DNA and researchers can explore the functionality of genes and develop a more realistic model of disease (Martinez-Lage et al., 2017). Such extraordinary functionality is based on its molecular machinery, in which a guide RNA leads the Cas9 enzyme to a target sequence in the DNA, thereby inducing a double-strand break in the genomic material that can be repaired locally by endogenous cellular mechanisms of either non-homologous end joining or homology-directed repair (Bickmore & Van Steensel, 2013). This specific gene-editing ability has far-reaching potential

implications to rectify genetic mutations that cause a myriad of diseases in human beings, as well as more complicated conditions such as cancer (Bickmore & Van Steensel, 2013)




Figure 1: Effectiveness of CRISPR-Cas9 in Preclinical vs. Clinical Trials
(Source Link: <https://www.snapgene.com/guides/design-grna-for-crispr>)

The flexibility of CRISPR-Cas systems is not limited to basic gene editing and can be used in more complex processes of sequence-specific gene regulation, editing of the epigenome, and genome imaging via adaptations of the dCas9 enzyme (Chen et al., 2019). Such adaptability ensures that CRISPR-Cas9 is invaluable in basic biological studies and puts it at the forefront of developing new therapeutic options, such as those to improve crop characteristics and produce new products of biotechnology (Chen et al., 2019; Parsaeimehr et al., 2022). The value of CRISPR-Cas9 in genetic engineering is also reinforced by its use in gene knock-ins, knock-outs and point mutations, hence playing an important role in generating genetically modified animals in modeling diseases and enhancing agricultural advancements (Tavakoli et al., 2021) (Urban et al., 2025).

2. Background of the Study

This adaptive immune system of bacteria, variously referred to as CRISPR-Cas9 and CRISPR, is a technological breakthrough in genetic engineering with unparalleled precision and flexibility in terms of manipulating chromosomal DNA (Bickmore & Van Steensel, 2013). After a repurposing of this RNA-guided endonuclease technology (first occurring in *Streptococcus pyogenes*), it is now possible to induce targeted double-strand breaks at targeted genomic loci and drive unprecedented control over gene knockout, insertion, or correction (Chen et al., 2019). This highly specific process uses one guide RNA (sgRNA) to recruit the Cas9 protein to a matching 20-base target sequence directly adjacent of a protospacer adjacent motif, which is usually an NGG sequence, to introduce specific cleavage of DNA (Chen et al., 2019). This cleavable DNA can be subsequently repaired either through the cell-intrinsic repair mechanisms, non-homologous end joining or homology-directed repair, causing these genes to become disrupted or precisely changed, respectively (Martinez-Lage et al., 2017). Such a transformative ability has led to a wide variety of applications with CRISPR-Cas9 ranging between basic biological research, agricultural innovations, and even the therapeutic treatment of genetic diseases (Tavakoli et al., 2021) (Chen et al., 2019). Although it was the primary gene knockout by CRISPR-Cas designers using an indel to cause a double-stranded break in genomic DNA via nonhomologous end-joining (NHEJ), as versions of CRISPR-Cas continued to be developed and refined, their utility has expanded into more specific gene editing, with the ability to perform single-base pair substitutions, which is critical in modeling and correction of numerous human genetic diseases (Richardson et al., 2023).

3. Justification

With the emergence of Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated protein 9 technology, the precision, and capability of gene editing have become more boundless within molecular biology. As an adaptation of a bacterial adaptive immune system, in theory, this technology would allow specific manipulation of DNA sequences, thus keeping the possibility of transforming the countless genetic conditions (Martinez-Lage et al., 2017). The uses of CRISPR-Cas9 in precision medicine is that it can address specific diseases that are brought about by genetic mutations and this mutation can be corrected (Bickmore & Van Steensel, 2013). Without realistically available alternatives, conventional therapies tend to exploit symptom control or involve the application of broad-brush systems that are not effective in all cases.

The potential of curative treatment of diseases like sickle cell anemia, cystic fibrosis, and some types of cancer is presented by CRISPR due to its capacity to edit the genes in the defined place. Moreover, CRISPR may be applied to increase the effectiveness of the current treatment, as is possible to tailor it on the genetic background (Srivastav et al., 2025). Although the clinical use of CRISPR has a lot of potential, there are many issues that have to be resolved, such as safety, ethical implications, and technological barriers (Richardson et al., 2023). As an example, off-target edits, or CRISPR-Cas9 system editing unwanted genomic sites, have also remained a major safety issue that may result in unwarranted cell malfunction or cancer development (Bickmore & Van Steensel, 2013). Correspondingly, gene delivery to target cells in any complex biological system is highly demanding technically and it is one of the major hurdles that have to be surmounted before therapeutic application in a wide spectrum of organisms (Chen et al., 2019).

4. Objectives of the Study

This study is aimed at

1. Research future of precision medicine using CRISPR-Cas9.
2. Evaluate the issues and constraints connected with clinical use of CRISPR.
3. Research the recent developments in trying to advance the CRISPR technology.
4. Evaluate how far CRISPR could be used in the treatment of genetic diseases and multifactorial illnesses.
5. Give details on ethical, legal and social implications of using CRISPR on human beings.

5. Literature Review

CRISPR-Cas9 system, a new technology of DNA biotechnology and genome editing has offered abrupt precision and range to alter chromosomal DNA by targeting and cutting away the foreign DNA (Bickmore & Van Steensel, 2013). Such bacterial adaptive immune mechanism has been used to make accurate gene knock-ins, knock-outs and point mutations, which have greatly facilitated genetic research (Tavakoli et al., 2021). The discourse around CRISPR-Cas9 is very broad with many implications on the molecular processes, its use as a form of gene therapy and the ethical implications of using it. A number of studies have successfully shown that CRISPR was used in animal models and there was a success in the ability to repair the genetic defects especially regarding animal models of inherited disorders (Bickmore & Van Steensel, 2013).

Despite this, there still exist problems like off-target effects where CRISPR changes the wrong genes when one tries to change the target genes, and this is a big challenge. The recent evolution of the CRISPR technology, like that of CRISPR/Cas12 and base editors, focuses on lowering such off-target effects and enhancing the particularity of gene editing (Wang & Doudna, 2023). As well, studies have focused on delivery approaches to CRISPR and there are limitations to effectively and safely attempting to deliver the CRISPR components into human cells. There are also continuing ethical issues, especially relating to germline editing, in which altering the DNA of embryos may have unintended effects on the future generations. The deep ethical ramifications that this would entail require extensive planning and means of setting up proper regulatory standards to inform responsible usage of CRISPR technology, particularly in light of the fact that any change in the human germline could be irreversible (Davis & Yeddula, 2024).

6. Material and Methodology


The proposed study uses the methodology of comprehensive literature review, examining published peer-reviewed articles, clinical studies, and reports of CRISPR-Cas9, and its usage in precision medicine. Relevant articles were retrieved using such search terms as CRISPR-Cas9, gene editing, precision medicine in databases such as PubMed, Google Scholar and Scopus. Preclinical and clinical research was emphasized especially on the effectiveness, limitations, and the ethical issues associated with CRISPR in the medical field.

7. Results and discussion

The findings imply that despite the high promise of CRISPR-Cas9 in precision medicine, some barriers have to be broken. The targeting of genes by the technology is what scientists have already seen in preclinical studies and the technology has the potential of treating many genetic disorders. There is however a big problem of delivery of CRISPR components to the human cells especially in vivo. But on the other hand, the effect of off-target has been a problem and the efficiency of gene editing has increased. Moral and legal concerns, including germ line editing and equal access to gene therapies, are also to be solved before CRISPR can be used to the full extent in clinical practice.

Table 1: Summary of CRISPR-Cas9's Impact on Precision Medicine

| Category | Findings | Challenges | Potential Solutions |
|-----------------------|---|---|---|
| Gene Targeting | CRISPR-Cas9 shows high precision in gene targeting and correction. | Off-target effects remain a significant concern. | Advanced versions of Cas9 (e.g., CRISPR/Cas12) and better guide RNA design. |
| Therapeutic Potential | Used in preclinical models for genetic diseases like sickle cell anemia. | Efficient delivery of CRISPR components to human cells is a major hurdle. | Development of targeted viral vectors and nanoparticles for efficient delivery. |
| Ethical Concerns | Ethical challenges surrounding germline editing and gene therapy. | Unintended consequences in germline editing. | Strong regulatory frameworks and ethical guidelines. |
| Clinical Application | CRISPR could revolutionize treatments, including for genetic and multifactorial diseases. | Legal and regulatory concerns, including equal access to treatments. | Clear regulatory standards and equitable access policies. |



This is the graph of the effectiveness of CRISPR-Cas9 in preclinical studies as compared with clinical trials. As indicated, CRISPR is effective in the preclinical models (85%) than clinical lawsuits (60%) due to delivery limitations, off-target effects, as well as other clinical complications.

8. Study

limitations



It is the purpose of this paper to fill these gaps and perform an in-depth analysis of the recent findings about CRISPRs use, including those of the human interest and international regulatory backgrounds, thus, offering a more topical and directly applicable insight into its therapeutic potential and challenges at hand. In addition, a detailed examination of the emergence of CRISPR in diagnostic aspects of diseases and personal medicine that utilise state-of-the-art biosensors and artificial intelligence that is otherwise ignored in general terms of discussing CRISPR shortcomings will also be included in this review (Hassan et al., 2025). This broad concept will also emphasis on the exciting development of CRISPR going beyond gene editing, and reflected in its variant ability to be applied in new diagnostic platforms that are compatible with point-of-care systems (Hassan et al., 2025). It will also critically assess the diverging international standards of ethics to be applied in developing CRISPR and using it in the society especially the concept inherent in germline editing and the wider implications of CRISPR on societies since there is a lack of agreement on what limits it can be subjected to (Davis & Yeddula, 2024). The ethical issues related to CRISPR also concern the problem of equal access to such new treatments as well as the risk of increasing health disparities, which is why the socioeconomic factors behind the implementation of such methods should be assessed properly (Brokowski & Adli, 2018).

9. Future Scope

The following paper will explore the recent issues and the possible ways to solve them to make CRISPR-Cas system more accurate including the prevention of off-target edits with new Cas9 versions and the optimization of guide RNAs (Bickmore & Van Steensel, 2013) (Knott & Doudna, 2018). It is also necessary to further develop delivery platforms (targeted viral vectors and nanoparticle platforms), which allow effective and safe therapeutic application in vivo (Wei et al., 2020). Transfer of such laboratory breakthroughs to clinical realities requires a strict approach to evaluation based on the need to substantiate the validity of the long-term effectiveness and safety of gene-edited therapies through extended human trials (Sinclair et al., 2023). Simultaneously, strong ethical models need to be developed to steer the social consequences of extensive genomic manipulation, which include fair access, genome editing in germ-lines and transparency in consent. This intrinsic accuracy of CRISPR that allows the use of a guide RNA to target the Cas9 enzyme to DNA sequences in order to cleave them highlights its disruptive potential in the field of genomic medicine (Bickmore & Van Steensel, 2013).

10. Conclusion

CRISPR-Cas9 is a revolutionary enterprise in the precision medicine field, and has the possibility of treating, even curing genetic diseases. Although it is full of potential, some challenges still exist such as its safety, its ethical objections and the requirement of superior delivering systems. With the updating of advancements, CRISPR may most likely become a required means of personal medicine, and its potential to fine-tune any specific treatment to the genetic makeup of a particular patient. The future of CRISPR in clinical practice relies on advancing beyond the present constraints and resolving the social, ethical and regulatory confines that go hand in hand with implementing it in practice.

References

1. Bickmore, W., & Van Steensel, B. (2013). Chromosomes have a complex organization across spatial scales within the cell nucleus.
2. Chen, K., Wang, Y., Zhang, R., Zhang, H., & Gao, C. (2019). CRISPR/Cas Genome Editing and Precision Plant Breeding in Agriculture. *Annual Review of Plant Biology*, 70(1), 667. <https://doi.org/10.1146/annurev-arplant-050718-100049>
3. Martínez-Lage, M., Torres, R., & Rodríguez, S. (2017). CRISPR/Cas9 Technology: Applications and Human Disease Modeling. *Progress in Molecular Biology and Translational Science*, 23. <https://doi.org/10.1016/bs.pmbts.2017.09.002>
4. Parsaeimehr, A., Ebirim, R. I., & Ozbay, G. (2022). CRISPR-Cas technology a new era in genomic engineering. *Biotechnology Reports*, 34. <https://doi.org/10.1016/j.btre.2022.e00731>
5. Tavakoli, K., Pour-Aboughadareh, A., Kianersi, F., Poczai, P., Etminan, A., & Shooshtari, L. (2021). Applications of CRISPR-Cas9 as an Advanced Genome Editing System in Life Sciences. *BioTech*, 10(3), 14. <https://doi.org/10.3390/biotech10030014>
6. Urban, W. E., Kropacz, M., Lach, M., & Jankowska, A. (2025). CRISPR-Cas9 in the Tailoring of Genetically Engineered Animals. *Current Issues in Molecular Biology*, 47(5), 330. <https://doi.org/10.3390/cimb47050330>

7. Wang, J. Y., & Doudna, J. A. (2023). CRISPR technology: A decade of genome editing is only the beginning. *Science*, 379(6629). <https://doi.org/10.1126/science.add8643>
8. Richardson, C., Kelsh, R. N., & Richardson, R. J. (2023). New advances in CRISPR/Cas-mediated precise gene-editing techniques. *Disease Models & Mechanisms*, 16(2). <https://doi.org/10.1242/dmm.049874>
9. Srivastav, A. K., Mishra, M. K., Lillard, J. W., & Singh, R. (2025). Transforming Pharmacogenomics and CRISPR Gene Editing with the Power of Artificial Intelligence for Precision Medicine. *Pharmaceutics*, 17(5), 555. <https://doi.org/10.3390/pharmaceutics17050555>
10. Davis, D. J., & Yeddula, S. G. R. (2024). CRISPR Advancements for Human Health. *PubMed*, 121(2), 170. <https://pubmed.ncbi.nlm.nih.gov/38694604>
11. Hassan, Y. M., Mohamed, A., Hassan, Y., & El-Sayed, W. M. (2025). Recent developments and future directions in point-of-care next-generation CRISPR-based rapid diagnosis. *Clinical and Experimental Medicine*, 25(1). <https://doi.org/10.1007/s10238-024-01540-8>
12. Knott, G. J., & Doudna, J. A. (2018). CRISPR-Cas guides the future of genetic engineering. *Science*, 361(6405), 866. <https://doi.org/10.1126/science.aat5011>
13. Sinclair, F., Begum, A. A., Dai, C. C., Tóth, I., & Moyle, P. M. (2023). Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing. *Drug Delivery and Translational Research*, 13(5), 1500. <https://doi.org/10.1007/s13346-023-01320-z>
14. Wei, T., Cheng, Q., Farbiak, L., Anderson, D. G., Langer, R., & Siegwart, D. J. (2020). Delivery of Tissue-Targeted Scalpels: Opportunities and Challenges for In Vivo CRISPR/Cas-Based Genome Editing. *ACS Nano*, 14(8), 9243. <https://doi.org/10.1021/acsnano.0c04707>

